Copper Toxicity Links to Pathogenesis of Alzheimer’s Disease and Therapeutics Approaches
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is an irreversible, age-related progressive neurological disorder, and the most common type of dementia in aged people. Neuropathological lesions of AD are neurofibrillary tangles (NFTs), and senile plaques comprise the accumulated amyloid-beta (Aβ), loaded with metal ions including Cu, Fe, or Zn. Some reports have identified metal dyshomeostasis as a neurotoxic factor of AD, among which Cu ions seem to be a central cationic metal in the formation of plaque and soluble oligomers, and have an essential role in the AD pathology. Cu-Aβ complex catalyzes the generation of reactive oxygen species (ROS) and results in oxidative damage. Several studies have indicated that oxidative stress plays a crucial role in the pathogenesis of AD. The connection of copper levels in AD is still ambiguous, as some researches indicate a Cu deficiency, while others show its higher content in AD, and therefore there is a need to increase and decrease its levels in animal models, respectively, to study which one is the cause. For more than twenty years, many in vitro studies have been devoted to identifying metals’ roles in Aβ accumulation, oxidative damage, and neurotoxicity. Towards the end, a short review of the modern therapeutic approach in chelation therapy, with the main focus on Cu ions, is discussed. Despite the lack of strong proofs of clinical advantage so far, the conjecture that using a therapeutic metal chelator is an effective strategy for AD remains popular. However, some recent reports of genetic-regulating copper transporters in AD models have shed light on treating this refractory disease. This review aims to succinctly present a better understanding of Cu ions’ current status in several AD features, and some conflicting reports are present herein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“The soluble oligomers obtained from the culturing of cells possess high chemical resistance and protect against its conversion into monomers via several degrading factors and maintain the presence of covalent cross-links in them [134,135].”
BackgroundRetractedSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“Though 20–40% of healthy cases have amyloid plaques, as illustrated by some studies [333].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“One of the most common neuropathological hallmarks of AD is the misfolding and aggregation of amyloid plaques-extracellular insoluble deposits of the β-amyloid peptides [21], and the intracellular formed NFTs (neurofibrillary tangles) [22], leading to the loss of communication between nerve cells, causes brain damage…”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Furthermore, in parallel, antibody-based treatment for Aβ aggregation is now developing and providing safe results as well [337].”
BackgroundThe role of the posterior cingulate cortex in cognition and disease
Leech, R., & Sharp, D. J. (2014) · Brain · doi:10.1093/brain/awt162 · Cited by 2,247 · cited 1×
“Posterior cingulated cortex (PCC) [24], entorhinal cortex (EC) [25], hippocampus (HIP) [26] (the first part to be affected by AD), middle temporal gyrus (MTG) (role in cognitive functions such as language processing), and superior frontal gyrus (SFG) (helps in memory) [27,28] are the regions affected in this multifact…”
BackgroundOxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 2×
“Copper-Aβ fibrils complex produces hydrogen peroxide (H2O2) in the presence of ascorbic acid, a biological reductant [175,176].”
BackgroundCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750 · cited 1×
“Senile plaques or amyloid plaques mainly consist of small amyloid beta-peptides (Aβ) (up to 42 or 43 amino acids long) [35].”
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“Much later, followed by the same approach, the first-generation of metal chelator, a lipophilic small molecule clioquinol (5-chloro-7-iodo-8HQ or CQ) was introduced at the end of the 1990s [244,255].”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
[18] Quantification of β-sheet amyloid fibril structures with thioflavin T
LeVine, H. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09020-5 · Cited by 1,365 · cited 1×
“The fluorescent dye thioflavin T (ThT), also known as Basic Yellow 1 or CI 49005, has been widely used to detect amyloid fibrils [292] in both in vivo and in vitro studies.”
BackgroundAdult hippocampal neurogenesis and its role in Alzheimer’s disease
Mu, Y., & Gage, F. H. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-85 · Cited by 1,021
Metals in Alzheimer's and Parkinson's Diseases
Barnham, K. J., & Bush, A. I. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.019 · Cited by 695 · cited 1×
“CQ reduced Aβ aggregation during Phase II trials and improved cognitive behavior, but failed to provide sufficient evidence of a positive clinical benefit in a larger clinical trial [256,257].”
BackgroundCurrent and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 2×
“However, AD’s exact etiology is still not well understood, and as such, there is no successful therapeutic option available for this disorder to date [96,97].”
BackgroundAdlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Atwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D. P., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751219.x · Cited by 641
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing
Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617 · cited 1×
“Much data have suggested that endo-lysosomal/autophagic dysfunction is responsible for soluble oligomeric forms and insoluble forms of tau aggregation (Figure 2) [170,171].”
BackgroundDeibel, M. A., Ehmann, W. D., & Markesbery, W. R. (1996) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00203-1 · Cited by 540
Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532 · cited 1×
“Reduction in the level of LRP-1 leads to further impairment in the transcytotic Aβ clearance and increased neuroinflammation [163].”
BackgroundInconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497 · cited 2×
“Therefore, some researchers were still showing promise for these compounds [325,332].”
BackgroundAqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion
Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., & Bush, A. I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23223 · Cited by 482
Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468
Levine, M. E., Lu, A. T., Bennett, D. A., & Horvath, S. (2015) · Aging · doi:10.18632/aging.100864 · Cited by 455
Synapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436 · cited 1×
“healthy neurons, such as communication, metabolism, and repair [9,10].”
BackgroundSantos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431 · cited 1×
“It is one of the leading causes of death [11] that we are currently unable to stop or cure because the underlying etiology is poorly understood at present [11,12].”
BackgroundThe age factor in Alzheimer’s disease
Guerreiro, R., & Bras, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0232-5 · Cited by 415
Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid
Vigo‐Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09841.x · Cited by 385
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Transgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332
Brain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306
La Joie, R., Perrotin, A., de La Sayette, V., Egret, S., Doeuvre, L., Belliard, S., Eustache, F., Desgranges, B., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.08.007 · Cited by 290
White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284
Hamano, T., Gendron, T. F., Causevic, E., Yen, S., Lin, W., Isidoro, C., DeTure, M., & Ko, L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06084.x · Cited by 283
Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus
Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917095514 · Cited by 236 · cited 1×
“One of the most common neuropathological hallmarks of AD is the misfolding and aggregation of amyloid plaques-extracellular insoluble deposits of the β-amyloid peptides [21], and the intracellular formed NFTs (neurofibrillary tangles) [22], leading to the loss of communication between nerve cells, causes brain damage…”
BackgroundHa, C., Ryu, J., & Park, C. B. (2007) · Biochemistry · doi:10.1021/bi7000032 · Cited by 231 · cited 1×
“A meta-analysis [149] and the following investigations [109,150] revealed a lower total Cu in AD, while the level of labile Cu is higher in most of the brain areas affected by this disease [109].”
BackgroundBifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide
Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 225 · cited 3×
“Several studies have analyzed the deposition of Aβ1-42 in the deficiencies and presence of essential metal ions [291,295].”
BackgroundRobert, A., Liu, Y., Nguyen, M., & Meunier, B. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00119 · Cited by 212 · cited 1×
“Indeed, only a few of them made their way to clinical trials [315,316].”
BackgroundSmall Molecule Modulators of Copper-Induced Aβ Aggregation
Hindo, S. S., Mancino, A. M., Braymer, J. J., Liu, Y., Vivekanandan, S., Ramamoorthy, A., & Lim, M. H. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907045h · Cited by 203 · cited 1×
“Choi (2011) and Hindo (2009) [302,303] reported the derived compounds and analyzed their impact on metal-binding properties, β-amyloid deposition both in deficiency and the presence of metal ions.”
BackgroundThe Role of the Microtubule Cytoskeleton in Neurodevelopmental Disorders
Lasser, M., Tiber, J., & Lowery, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00165 · Cited by 201
Sarell, C. J., Wilkinson, S. R., & Viles, J. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.171355 · Cited by 199 · cited 4×
“While, the dietary copper addition leads to an increase of intracellular copper concentration in APP/PS1 AD mice [160], which has been shown in parenchymal Aβ plaques, a decrease of AD pathology, but no loss of neurons seen [152,153].”
BackgroundInfluentialCopper excess, zinc deficiency, and cognition loss in Alzheimer's disease
Brewer, G. J. (2012) · BioFactors · doi:10.1002/biof.1005 · Cited by 188
Tõugu, V., Karafin, A., Zovo, K., Chung, R. S., Howells, C., West, A. K., & Palumaa, P. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06269.x · Cited by 181
Rapid cell death is preceded by amyloid plaque-mediated oxidative stress
Xie, H., Hou, S., Jiang, J., Sekutowicz, M., Kelly, J., & Bacskai, B. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217938110 · Cited by 172
Kitazawa, M., Cheng, D., & LaFerla, F. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05901.x · Cited by 165
Castillo, E., Leon, J., Mazzei, G., Abolhassani, N., Haruyama, N., Saito, T., Saido, T., Hokama, M., Iwaki, T., Ohara, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17999-3 · Cited by 158
Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease
Perez, L. R., & Franz, K. J. (2010) · Dalton Trans. · doi:10.1039/b919237a · Cited by 156
Storr, T., Merkel, M., Song-Zhao, G. X., Scott, L. E., Green, D. E., Bowen, M. L., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068965r · Cited by 156 · cited 1×
“Various analogs of boronic ester, such as boronic esters (BSIH, BSBH) and acids (BASIH), have been investigated to check their performance as metal chelators [312].”
BackgroundRodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151 · cited 7×
“Post-hoc study of the Phase 2A trials claimed that PBT2 improves cognition in AD [330], though, the results of this clinical trial are in question.”
BackgroundInfluentialPreliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141 · cited 1×
“molecular fragments of different specificities to make a hybrid molecule [293].”
BackgroundCheignon, C., Jones, M., Atrián-Blasco, E., Kieffer, I., Faller, P., Collin, F., & Hureau, C. (2017) · Chemical Science · doi:10.1039/c7sc00809k · Cited by 132
Ma, Q., Li, Y., Du, J., Liu, H., Kanazawa, K., Nemoto, T., Nakanishi, H., & Zhao, Y. (2006) · Peptides · doi:10.1016/j.peptides.2005.09.002 · Cited by 123
Hippocampal shape analysis in Alzheimer's disease and frontotemporal lobar degeneration subtypes
Lindberg, O., Walterfang, M., Looi, J. C. L., Malykhin, N., Östberg, P., Zandbelt, B., Styner, M., Paniagua, B., Velakoulis, D., Örndahl, E., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112210 · Cited by 103
Mold, M., Ouro-Gnao, L., Wieckowski, B. M., & Exley, C. (2013) · Scientific Reports · doi:10.1038/srep01256 · Cited by 101 · cited 3×
“While, the dietary copper addition leads to an increase of intracellular copper concentration in APP/PS1 AD mice [160], which has been shown in parenchymal Aβ plaques, a decrease of AD pathology, but no loss of neurons seen [152,153].”
BackgroundXu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27524 · Cited by 85
The curious case of clioquinol
Cahoon, L. (2009) · Nature Medicine · doi:10.1038/nm0409-356 · Cited by 83 · cited 1×
“Much later, followed by the same approach, the first-generation of metal chelator, a lipophilic small molecule clioquinol (5-chloro-7-iodo-8HQ or CQ) was introduced at the end of the 1990s [244,255].”
BackgroundCheignon, C., Faller, P., Testemale, D., Hureau, C., & Collin, F. (2016) · Metallomics · doi:10.1039/c6mt00150e · Cited by 81 · cited 1×
“Cu ions interaction with Aβ results in its accumulation under a slightly acidic environment and promotes ROS production in Alzheimer’s pati nts [183].”
BackgroundScott, L. E., Telpoukhovskaia, M., Rodríguez-Rodríguez, C., Merkel, M., Bowen, M. L., Page, B. D. G., Green, D. E., Storr, T., Thomas, F., Allen, D. D., et al. (2011) · Chem. Sci. · doi:10.1039/c0sc00544d · Cited by 68 · cited 1×
“Besides metal ions’ chelation role in Alzheimer’s, new chelating molecules such as phenyl benzotriazole followed by the same design principle of thioflavin-T(ThT), correlating them with dipicolylamine or pyrinophane type metal chelators have been reported by the studies [277,302,306,309].”
BackgroundExley, C., House, E., Polwart, A., & Esiri, M. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120766 · Cited by 59 · cited 1×
“Cu concentration of the elderly has a direct relation with Aβ aggregation [86].”
BackgroundSharma, A. K., Kim, J., Prior, J. T., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2014) · Inorganic Chemistry · doi:10.1021/ic500926c · Cited by 53 · cited 2×
“It is now undeniable that the next generation of therapies should have the ability to target the different causes of disease progression at the same time [287].”
BackgroundPickart, L., Vasquez-Soltero, J., & Margolina, A. (2017) · Brain Sciences · doi:10.3390/brainsci7020020 · Cited by 51
Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation
Choi, J.-S., Braymer, J. J., Park, S. K., Mustafa, S., Chae, J., & Lim, M. H. (2011) · Metallomics · doi:10.1039/c0mt00077a · Cited by 41 · cited 2×
“Besides metal ions’ chelation role in Alzheimer’s, new chelating molecules such as phenyl benzotriazole followed by the same design principle of thioflavin-T(ThT), correlating them with dipicolylamine or pyrinophane type metal chelators have been reported by the studies [277,302,306,309].”
BackgroundProsdocimi, T., De Gioia, L., Zampella, G., & Bertini, L. (2016) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-015-1322-y · Cited by 32
The role of copper and the copper-related protein CUTA in mediating APP processing and Aβ generation
Hou, P., Liu, G., Zhao, Y., Shi, Z., Zheng, Q., Bu, G., Xu, H., & Zhang, Y.-W. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.005 · Cited by 32 · cited 2×
“Contrarily, Cu ions do not cause neurotoxicity in the absence of amyloid peptides [158].”
Background
Cited by
Copper metabolism in cell death and autophagy
Xue, Q., Kang, R., Klionsky, D. J., Tang, D., Liu, J., & Chen, X. (2023) · Autophagy · doi:10.1080/15548627.2023.2200554 · Cited by 701
Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications
Gromadzka, G., Tarnacka, B., Flaga, A., & Adamczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239259 · Cited by 339
Althobaiti, N. A. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115212 · Cited by 64
Zhang, Q., Zhao, W., Hou, Y., Song, X., Yu, H., Tan, J., Zhou, Y., & Zhang, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14132 · Cited by 40
Gonzalez, P., Sabater, L., Mathieu, E., Faller, P., & Hureau, C. (2022) · Biomolecules · doi:10.3390/biom12101327 · Cited by 13
Metadata
- Authors
- Ejaz, H. W., Wang, W., & Lang, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-16
- Volume
- 21
- Issue
- 20
- Pages
- 7660
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3096976771
- Cited by
- 143
- References
- 67
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.